Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Distillery Therapeutics

RUNX1 inhibition via dominant negative mRNA construct for vitreoretinal disease

BC Staff
January 28, 2025 12:45 AM UTC

An mRNA construct encoding a fusion protein inhibitor of RUNX1, a transcription factor that drives epithelial-to-mesenchymal transition (EMT) in proliferative vitreoretinopathy (PVR), could help treat PVR by reducing pathological epiretinal membrane growth.

In epiretinal membranes from PVR patients, RUNX1 expression was detected in all cell types within the tissue, and was associated with expression of EMT-associated genes. ...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Curevac N.V.

Schepens Eye Research Institute